Of relevance to this editorial focus is the report from Souza and colleagues (6) at the Universidade de São Paulo who reported that ET-1 not only caused fever after introcerebroventricular (ICV) injection into rats, but that an ET B receptor antagonist attenuated fevers due to systemically administered LPS and IL-1␤, as well as to ICV IL-1␤ or TNF-␣. What was particularly interesting about this observation was that the hyperthermic response to ET-1 was not modified by the cyclooxygenase (COX) inhibitor indomethacin, suggesting that PGs were not involved. A subsequent paper (7) further investigated the involvement of PGs with the use of specific COX-2 inhibitors, but the data are somewhat confusing. The COX-2 inhibitors celecoxib and lumiracoxib reduced cerebrospinal fluid PG induced by either LPS or ICV ET-1, but the fever induced by ET-1 was not attenuated, at least at the doses effective in reducing the PG levels. On the basis of these results, the authors again suggested that there may be ET-1-dependent febrile actions independent of PGs.
In this issue of the journal, these authors (5) again attempt to unravel the role of ET-1 and its receptors in fever, in particular, addressing its possible involvement in non-PG-dependent fevers. With the use of various selective receptor antagonists, they have concluded that several parallel pathways within the brain are activated by peripherally administered LPS, with ET-1 being an intermediary in a pathway involving sequential release/action of a still uncharacterized factor called preformed pyrogenic factor, corticotrophin-releasing hormone, ET-1 (via ET B receptors), and finally IL-1␤. This pathway is independent of, but parallel to, other pathways also involving ILs, TNF-␣, PGE 2 These interesting findings raise numerous questions and avenues for further investigation. Key questions, yet unaddressed, arise from these findings. Under what conditions do each of these pathways contribute to fever? Are they activated in response to different doses of LPS or in response to different signaling pathways to the brain? Are these different pathways activated at different times of the febrile process? It is interesting that ICV ET-1 fevers have an onset latency of 2 h, with a peak around 4 -6 h. LPS-induced fevers consist of at least three phases (21), most likely due to several waves of pyrogenic and antipyretic molecules. On the basis of its long latency of action, ET-1 may be a candidate for the latter phases of the fever.
Non-PG-dependent fevers remain poorly understood, and the mechanisms of their development remain obscure. At least in mice, all evidence indicates that absence of either specific PG receptors (20, 25) or COX-2 (15) abolishes fever to LPS. If a similar situation were to exist in rats, one might ask why a non-PG-dependent pathway, possibly involving ET-1, would not support a fever in a PG-deficient rodent?
As a peptide molecule, it is unlikely that ET-1 can enter the brain from the periphery. The present study thus appears to implicate brain ET-1 as a mediator of the febrile process. This is quite possible because ETs are synthesized in the brain, largely in astrocytes (9) , and their receptors are widely distributed throughout neuronal tissue (13) . Nonetheless, vascular endothelial cells produce ET-1 in response to LPS (22) , and peripheral administration of LPS, at least in large doses, is associated with measurable levels of ET-1 in the plasma (19) . A site where there are numerous ET B receptors is the subfornical organ (9) , which is outside the blood-brain barrier, and the action of systemic ET-1 on hypothalamic neuronal activity has been shown to be dependent on subfornical organ integrity (26) . Because this structure is also accessible from the cerebral ventricles, one cannot eliminate the possibility that the effects on body temperature due to ICV administration of ET-1 or of receptor antagonists, reflect the action of circulating ET-1 rather than that which is centrally produced.
Finally, the use of ICV injections to investigate neurotransmitter pathways in the brain provides a useful first approach to implicating this peptide in fever. Future studies must address the anatomical specificity of the various parallel pathways. It would also be useful to investigate LPS fever in ET-1 or ET receptor knockout mice (13) . Whatever the outcome of such studies, it is apparent from the present study (5) that ET has emerged as a significant player in the inflammatory process. Thus like a number of other peptides, a former "cardiovascular" peptide has an action on a distinctly different autonomic function, in this case, fever.
